Ispinesib

DB06188InvestigationalSmall molecule

Investigated for use/treatment in breast cancer, lung cancer, solid tumors, renal cell carcinoma, pediatric indications, ovarian cancer, and head and neck cancer.

Mechanism: Pharmacologically active on Kinesin-like protein KIF11
Curator reviewed
Primary indication: Investigated for use/treatment in breast cancer, lung cancer, solid tumors, renal cell carcinoma, pediatric indications, ovarian cancer, and head and neck cancer.Curator reviewed
Formula / weight: C₃₀H₃₃ClN₄O₂ · 517.07 g/mol (avg)
Code names: CK-0238273 · SB-715992

Resolves to

Compound

UNIIBKT5F9C2NICAS336113-53-2ChEMBLCHEMBL228814ChEBI94692

Structure

InChIKeyQJZRFPJCWMNVAV-HHHXNRCGSA-NSMILESCC(C)[C@@H](N(CCCN)C(=O)C1=CC=C(C)C=C1)C1=NC2=CC(Cl)=CC=C2C(=O)N1CC1=CC=CC=C1

Targets

P52732KIF11

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

14Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ispinesib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account